A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of VS-6766 monotherapy and in combination with
Defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Phase:
Phase 2
Details
Lead Sponsor:
Verastem, Inc.
Collaborators:
European Network of Gynaecological Oncological Trial Groups (ENGOT) GOG Foundation Gynecologic Oncology Group